Further studies should concentrate on metabolic pathways known to be altered in OA including PC-lysoPC-LPA, BCAA-mTOR, and arginine-NO/l-ornithine pathways and their links to other comorbidities with common metabolite profile changes including diabetes, depression, and cardiovascular disease. Here, MTOR is linked to depressive symptom measurement.